Mirzaei Siroos, Lipp Rainer, Zandieh Shahin, Leisser Asha
Department of Nuclear Medicine with PET-Center, Clinic Ottakring (Wilhelminenspital), 1160 Vienna, Austria.
Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
Curr Oncol. 2021 Oct 15;28(5):4167-4173. doi: 10.3390/curroncol28050353.
the diagnostic performance of [Cu]-DOTAGA-PSMA PET-CT imaging was compared retrospectively to [F]-PSMA PET-CT in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local and possible metastatic disease.
We retrospectively selected a total of 100 patients, who were consecutively examined in our department, with biochemical recurrence after radical prostatectomy or who had progressive local and possible metastatic disease in the last 3 months prior to this investigation. All patients were examined with a dedicated PET-CT scanner (Biograph; Siemens Healthineers). A total of 250 MBq (3.5 MBq per kg bodyweight, range 230-290 MBq) of [Cu]-DOTAGA-PSMA or [-F]-PSMA was applied intravenously. PET images were performed 1 h post-injection (skull base to mid-thigh). The maximum standardized uptake values (SUVmax) of PSMA-positive lesions and the mean standardized uptake value (SUVmean) of the right liver lobe were measured.
All but 9/50 of the patients (18%; PSA range: 0.01-0.7 µg/L) studied with [Cu]-DOTAGA-PSMA and 6/50 of the ones (12%; PSA range: 0.01-4.2) studied with [F]-PSMA had at least one positive PSMA lesion shown by PET-CT. The total number of lesions was higher with [Cu]-DOTAGA-PSMA (209 vs. 191); however, the median number of lesions was one for [Cu]-DOTAGA-PSMA and two for [F]-PSMA. Interestingly, the median SUVmean of the right liver lobe was slightly higher for [F]-PSMA (11.8 vs. 8.9).
[Cu]-DOTAGA-PSMA and [F]-PSMA have comparable detection rates for the assessment of residual disease in patients with recurrent or primary progressive prostate cancer. The uptake in the liver is moderately different, and therefore at least the SUVs of the lesions in both studies would not be comparable.
对[铜]-DOTAGA-PSMA PET-CT成像在复发性疾病的前列腺癌患者以及部分局部晚期和可能有转移疾病患者的初次分期中的诊断性能，与[氟]-PSMA PET-CT进行了回顾性比较。
我们回顾性选择了总共100例患者，这些患者在我们科室接受了连续检查，包括前列腺癌根治术后生化复发的患者，或在本次研究前最后3个月内有局部进展且可能有转移疾病的患者。所有患者均使用专用PET-CT扫描仪（Biograph；西门子医疗）进行检查。静脉注射250 MBq（每千克体重3.5 MBq，范围230 - 290 MBq）的[铜]-DOTAGA-PSMA或[氟]-PSMA。注射后1小时（从颅底至大腿中部）进行PET图像采集。测量PSMA阳性病变的最大标准化摄取值（SUVmax）以及右肝叶的平均标准化摄取值（SUVmean）。
使用[铜]-DOTAGA-PSMA研究的患者中，除9/50（18%；PSA范围：0.01 - 0.7 µg/L）外，以及使用[氟]-PSMA研究的患者中6/50（12%；PSA范围：0.01 - 4.2）外，至少有一个PSMA阳性病变通过PET-CT显示。[铜]-DOTAGA-PSMA显示的病变总数更多（209个对191个）；然而，[铜]-DOTAGA-PSMA的病变中位数为1个，[氟]-PSMA为2个。有趣的是，[氟]-PSMA的右肝叶SUVmean中位数略高（11.8对8.9）。
[铜]-DOTAGA-PSMA和[氟]-PSMA在评估复发性或原发性进展性前列腺癌患者的残留疾病方面具有可比的检测率。肝脏摄取存在适度差异，因此至少两项研究中病变的SUV值不可比。
